Status: Recruiting
CelluJuve® for the Treatment of Moderate to Severe NLFs
Single-center, open-label proof of concept study assessing the safety and effectiveness of CelluJuve® for the treatment of moderate to severe NLFs
Participants needed: 12
Trial details
Age: 22+Biological sex: AllType: InterventionalSponsor: Spiderwort Biotechnologies Inc.Updated: May 22, 2026Locations: 1
Eligibility criteria
Male or female of any race, 22 years of age or older, who are seeking therapy fo... [+4]
Female subjects that are pregnant, breast-feeding, or of childbearing potential... [+22]